Privately held Personalized Medicine company focused on discovery & clinical application of genomic signatures predictive of susceptibility to diseases, their complications & individual therapeutic responsiveness. The company has made significant progress in the identification of the genomic features associated with complications of type II diabetes. Based on these findings Prognomix has developed a prototype of a molecular diagnostic kit that will include clinical, genomic & epigenomic markers.